- Home
- IOBT vs AVTX Comparison
IOBT vs AVTX Comparison
Compare IOBT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- AVTX
- Stock Information
- Founded
- IOBT 2014
- AVTX 2011
- Country
- IOBT Denmark
- AVTX United States
- Employees
- IOBT N/A
- AVTX N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- AVTX Health Care
- Exchange
- IOBT Nasdaq
- AVTX Nasdaq
- Market Cap
- IOBT 81.7M
- AVTX 90.9M
- IPO Year
- IOBT 2021
- AVTX 2015
- Fundamental
- Price
- IOBT $0.89
- AVTX $12.92
- Analyst Decision
- IOBT Strong Buy
- AVTX Buy
- Analyst Count
- IOBT 3
- AVTX 2
- Target Price
- IOBT $9.33
- AVTX $35.00
- AVG Volume (30 Days)
- IOBT 279.8K
- AVTX 61.9K
- Earning Date
- IOBT 11-12-2024
- AVTX 11-07-2024
- Dividend Yield
- IOBT N/A
- AVTX N/A
- EPS Growth
- IOBT N/A
- AVTX N/A
- EPS
- IOBT N/A
- AVTX N/A
- Revenue
- IOBT N/A
- AVTX $820,000.00
- Revenue This Year
- IOBT N/A
- AVTX N/A
- Revenue Next Year
- IOBT N/A
- AVTX N/A
- P/E Ratio
- IOBT N/A
- AVTX N/A
- Revenue Growth
- IOBT N/A
- AVTX N/A
- 52 Week Low
- IOBT $0.73
- AVTX $3.95
- 52 Week High
- IOBT $2.10
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- IOBT 33.52
- AVTX 60.42
- Support Level
- IOBT $0.86
- AVTX $12.00
- Resistance Level
- IOBT $1.29
- AVTX $13.31
- Average True Range (ATR)
- IOBT 0.12
- AVTX 1.11
- MACD
- IOBT -0.04
- AVTX -0.10
- Stochastic Oscillator
- IOBT 7.15
- AVTX 35.32
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).